Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain TSRO message board posts where the ticker symbol TSRO has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest TSRO SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, item 8.01
Acc-no: 0001104659-17-072049 (34 Act)  Size: 22 KB
2017-12-06 001-35587
171241659
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001104659-17-071945 Size: 8 KB
2017-12-05
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-17-010272 (34 Act)  Size: 10 KB
2017-12-04 001-35587
171235864
8-K  Documents Current report, items 1.01 and 2.03
Acc-no: 0001104659-17-069758 (34 Act)  Size: 30 KB
2017-11-21 001-35587
171215401
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001104659-17-069672 Size: 5 KB
2017-11-20
8-K  Documents Current report, item 5.02
Acc-no: 0001104659-17-068014 (34 Act)  Size: 21 KB
2017-11-13 001-35587
171196880
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001558370-17-008418 (34 Act)  Size: 8 MB
2017-11-07 001-35587
171184376
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001104659-17-066634 (34 Act)  Size: 198 KB
2017-11-07 001-35587
171183460
8-K  Documents Current report, items 5.02, 7.01, and 9.01
Acc-no: 0001104659-17-064389 (34 Act)  Size: 59 KB
2017-10-27 001-35587
171160089
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-17-008888 (34 Act)  Size: 11 KB
2017-09-26 001-35587
171100952
More TSRO SEC Filings


Related news from
Fri, 08 Dec 2017
13:06:23 +0000
See what the IHS Markit Score report has to say about TESARO Inc.
TESARO Inc NASDAQ/NGS:TSRO
Tue, 05 Dec 2017
18:22:06 +0000
ETFs with exposure to TESARO, Inc. : December 5, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TESARO, Inc. Here are 5 ETFs with the largest exposure to TSRO-US. Comparing the performance and risk of TESARO, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more <b>(Read more...)</b>
Fri, 01 Dec 2017
13:00:00 +0000
Market Trends Toward New Normal in Infinity Pharmaceuticals, Edison International, Anthem, TESARO, Brunswick, and BroadSoft — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Dec. 01, 2017-- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ...
Tue, 28 Nov 2017
16:58:00 +0000
Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte
After a very strong year, the biotech sector has suffered an 8% pullback over the past 5 weeks. Todd Hagopian, whose biotech portfolio is up 38% this year, believes that the recent pullback has created bargains in Alexion, Flexion, Clovis, Tesaro, and Incyte.
Tue, 28 Nov 2017
13:00:00 +0000
TESARO Announces Availability of VARUBI® (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States
VARUBI injectable emulsion features ready-to-use, single-dose vial No saline, reconstitution or mixing is required to utilize VARUBI IV New formulation offers healthcare providers flexibility in their ...
Fri, 24 Nov 2017
16:24:04 +0000
3 Companies Competing to Gain Lead in Ovarian Cancer Market
Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.
Fri, 24 Nov 2017
15:56:23 +0000
ETFs with exposure to TESARO, Inc. : November 24, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to TESARO, Inc. Here are 5 ETFs with the largest exposure to TSRO-US. Comparing the performance and risk of TESARO, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more <b>(Read more...)</b>
Wed, 22 Nov 2017
21:05:00 +0000
TESARO Announces Participation in Two Investor Conferences
WALTHAM, Mass., Nov. 22, 2017-- TESARO, Inc., an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The Citi 2017 Global Healthcare Conference ...
Wed, 22 Nov 2017
12:35:12 +0000
Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks
FDA approval for Ultragenyx's (RARE) rare disease drug and pipeline setbacks faced by Acorda and Cytokinetics were the main news this week in the biotech sector.
Tue, 21 Nov 2017
15:25:03 +0000
TESARO (TSRO) Ovarian Cancer Drug Zejula Gets Approval in EU
TESARO (TSRO) received a boost with the approval of Zejula in Europe for ovarian cancer, following its approval in the United States earlier this year.
Tue, 21 Nov 2017
13:00:00 +0000
TESARO Secures $500 Million Non-Dilutive Term Loan Financing
WALTHAM, Mass., Nov. 21, 2017-- TESARO, Inc., an oncology focused biopharmaceutical company, announced today that it has entered into a definitive term loan agreement with BIOPHARMA CREDIT PLC and BIOPHARMA ...
Mon, 20 Nov 2017
14:24:00 +0000
DBV Rises On Phase 3 Results for Peanut Allergy Treatment -- Biotech Movers
The Montrouge, France-based firm unveiled positive topline results from its Phase 3 Realise study of peanut allergy treatment Viaskin Peanut.
Mon, 20 Nov 2017
13:00:00 +0000
TESARO’s Mary Lynne Hedley and Lonnie Moulder Named EY National Entrepreneurs of the Year®
WALTHAM, Mass., Nov. 20, 2017-- TESARO, Inc., an oncology-focused biopharmaceutical company, is proud to announce that co-founders Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President and COO, ...
Mon, 20 Nov 2017
12:01:01 +0000
TESARO Announces European Commission Approval of ZEJULA® for Women With Recurrent Ovarian Cancer
ZEJULA is the first PARP inhibitor approved in Europe for women with recurrent ovarian cancer, regardless of  BRCA  mutation or biomarker status Approval supported by robust data from a randomized, well-controlled ...
Wed, 15 Nov 2017
19:09:00 +0000
Tesaro Stock Could Have 41% Upside
For months now, investors have worried that Tesaro (TSRO) has lost its edge as it faces increased competition for its ovarian cancer drug Zejula. Today, Leerink analyst Seamus Fernandez upgraded the drug maker to an Outperform with a $121 price target. In short, Fernandez sees the drug maker’s stock gaining more than 41% over the next 12 months.
Mon, 13 Nov 2017
11:41:07 +0000
Edited Transcript of TSRO earnings conference call or presentation 7-Nov-17 9:15pm GMT
Q3 2017 TESARO Inc Earnings Call
Fri, 10 Nov 2017
15:02:02 +0000
TESARO, Inc. :TSRO-US: Earnings Analysis: Q3, 2017 By the Numbers : November 10, 2017
Categories: Yahoo FinanceGet free summary analysis TESARO, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of TESARO, Inc. – Clovis Oncology, Inc., ZIOPHARM Oncology, Inc., Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Insys Therapeutics, Inc. and Pfizer Inc. (CLVS-US, ZIOP-US, AMGN-US, MRK-US, BMY-US, ... Read more <b>(Read more...)</b>



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "At VF I have met some of the greatest givers from all walks of life and from all parts of the world. I thank each of them for sharing part of their life and knowledge with me." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards